SHENYANG XINGQI PHARMACEUTICAL CO.(SZ:300573) Ge Long Hui·2025-12-07 08:32Core Viewpoint - The announcement indicates that the company, Xingqi Eye Pharmaceutical, has successfully maintained its products in the National Medical Insurance Drug List, which is crucial for its market position and revenue stability [1] Group 1: Company Products - A total of 39 products from the company will continue to be included in the National Medical Insurance Drug List, with 8 classified as Category A and 31 as Category B [1] - Key products such as Cyclosporine Eye Drops (II), Compound Electrolyte Eye Irrigation Solution, and Sodium Hyaluronate Eye Drops remain in the National Medical Insurance List, indicating strong product performance and market acceptance [1] - The company has not experienced any product withdrawals from the National Medical Insurance Drug List, which reflects positively on its product portfolio and regulatory compliance [1]